by United Pompe | Jan 18, 2016 | News
Genzyme Study of Myozyme® for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
by United Pompe | Jan 18, 2016 | News
Cranbury, NJ, DECEMBER 14, 2006 – Amicus Therapeutics, a biopharmaceutical company developing small molecule, orally-administered pharmacological chaperones for the treatment of human genetic diseases, today announced that it has commenced Phase 1 clinical trials for...
by United Pompe | Jan 18, 2016 | News
Date: April 3, 2006 Product is First Treatment for Pompe Disease Genzyme Corp. (Nasdaq: GENZ) announced today that it has received marketing authorization for Myozyme® (alglucosidase alfa) in the European Union. Myozyme has been approved for long-term enzyme...
by United Pompe | Jan 18, 2016 | News
Date: January 17, 2006 Genzyme Corp. (Nasdaq: GENZ) announced today that the Food and Drug Administration has extended by 90 days the review period for the biologics license application for Myozyme® (alglucosidase alfa). The new action date for the application is...
by United Pompe | Jan 18, 2016 | News
Date: January 27, 2006 Proposed Indication Includes All Patients with Pompe Disease Genzyme Corp. (Nasdaq: GENZ) announced today that the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency has adopted a positive opinion on the marketing...
